Market debates varying cash transaction charges at surging BSE Limited

Market pulse

From the investor's mind

Tatva Chintan Pharma Chem is seeing early traction in its electrolyte salts business, where revenue grew to 6 crore rupees in the first quarter from just 1 crore rupees in the previous year. While this segment remains small for now, management is targeting a scale-up to 40 to 60 crore rupees in revenue. Shashank Udupa notes that if this expansion succeeds, the electrolyte salts business could emerge as a meaningful new growth driver for the company, diversifying its revenue streams beyond its core structure directing agents business.

Word in the street

BSE Limited

Investors are closely discussing BSE Limited, whose stock has risen 51.89 percent over the past year, bringing its market cap to about 1,63,979 crore. The core of the conversation revolves around its cash volume transaction charges, which are not uniform. The exchange levies normal rates on liquid stocks but significantly higher special rate charges for penny stocks, T2T stocks, and other categories. Consequently, a linear correlation between cash turnover and revenue assumptions cannot be made. Observers note the average daily turnover of the stock ranges from 600 to 1,200 crore on the NSE, making it an active point of analysis.

Yesterday's big moves

“The time of maximum pessimism is the best time to buy.”

John Templeton